Exclusive: ACR Convergence 2024 | Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Conditions
FocusRheum
Guidance
Drug Updates
- Analgesics
- Biologics/DMARDs
Practice Support
- Billing/Coding
- EMRs
- Facility
- Insurance
- QA/QI
- Technology
- Workforce
Opinion
Career
ACR
Search

Opinion: Help Bring Drug Prices Down

Maarten Boers, MSc, MD, PhD | August 22, 2017

Page: 1 2 3 | Single Page

Share:

Filed under:Biologics/DMARDs Opinion Speak Out Rheum Tagged with:Institute for Clinical and Economic Review (ICER)PATA Patient Access to Treatment Act

Related Articles

Institute for Clinical Economic Review Final Report on RA Treatments

May 4, 2017

On April 7, 2017, the Institute for Clinical and Economic Review (ICER) published its final report, titled, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.1 The stated objective of the report was to assess the comparative clinical effectiveness of the targeted immune modulators (TIMs) used to treat patients with moderate to severe active rheumatoid…

ACR Comments Help Inform ICER Assessment of Treatments for Lupus Nephritis & Other Rheumatic Conditions

October 19, 2020

The ACR submitted comments to the Institute for Clinical & Economic Review outlining key considerations that should inform independent assessment of the efficacy and cost-effectiveness of medical therapies for lupus nephritis.

Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

October 9, 2019

NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…

Total Knee Replacement Cost-Effective, Even with Obesity & Comorbidities

March 29, 2021

(Reuters Health)—Total knee replacement surgery can be a cost-effective procedure for patients with severe obesity and osteoarthritis (OA), even when they also have comorbidities such as cardiovascular disease or type 2 diabetes, a new study suggests. Researchers did a cost-benefit analysis for two patient populations (over 65 years, and age 50 to 65) who had…

About Us
Meet the Editors
Issue Archives
Contribute
Advertise
Contact Us

Copyright © 2000-2024 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
DEI Statement
Privacy Policy
Terms of Use
Cookie Preferences